Furthermore, mice with defective IL-17A signaling (by IL-17A knockout or IL-17A neutralization, or by enhancing the dominance of immunosuppressive Treg) were protected from liver fibrosis and NAFLD progression (11, 32, 33). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.